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Exosomes are important in intercellular communication. They assure the horizontal transfer of specific functional contents (i.e.,
proteins, lipids, RNA molecules, and circulating DNA) from donor to recipient cells. Notably, tumor-derived exosomes (TDEs)
appear to be an important vehicle of specific signals in cancer, impacting on tumor growth and metastasis. Recent researches
point to the characterization of exosomes in Hepatocellular Carcinoma (HCC), the major adult liver malignancy. In this review, we
summarize current findings onHCC exosomes, focusing on the identification of noncoding RNAs as exosome-enriched functional
regulators and new potential biomarkers. The great potential of exosomes in future HCC diagnostic and therapeutic approaches is
underlined.
1. Introduction
Exosomes are 40–100 nm extracellular vesicles (EV),
enriched in endosome-derived components that are secreted
both in physiological and pathological conditions by most,
if not all, cell types [1]. These vesicles originate inside
multivesicular bodies (MVBs) and are secreted by fusion
of the MVBs with the plasma membrane. Secreted vesicles
may be taken up by neighboring cells or be carried to distant
sites assuring that their specific content (i.e., proteins, lipids,
RNA molecules, and cell-free circulating DNA (cirDNA;
[2]) is horizontally transferred from donor to recipient cells.
Notably, exosome cargoes are thought to be stably protected
against degradation by the membrane vesicle itself. All
of these properties contribute to the role of exosomes in
intercellular communication, deeply impacting on a large
spectrum of cellular activities. In this light, growing evidence
points to tumor-derived exosomes (TDEs) as important
vehicle of specific signals in tumor onset and progression
(reviewed by [3]).
Studies on exosomes composition are limited; however,
with respect to Hepatocellular Carcinoma- (HCC-) derived
EVs, several observations suggest that the exosome cargoes
contribute to the metastatic progression as well as to the
acquisition of chemoresistance. HCC develops in the context
of cirrhosis and chronic inflammation and it is conceiv-
able that exosome-mediated cross-talk between different
cell types may contribute to propagation and amplification
of oncogenic signals [4]. Coherently, in the injured liver,
increased extracellular vesicle release from damaged hepato-
cytes, Kupffer cells, immune cell infiltrates, endothelial cells,
and hepatic stellate cells has been observed.
In this review, we firstly summarize the state of the
art of exosome research in cancer. Secondly, we focus
on exosomes in HCC, specifically providing an overview
on the biological role of the up today known noncod-
ing RNA (ncRNA) exosome cargoes. Finally, we highlight
that targeting the cell-cell communication mediated by
exosomes represents a promising approach in anticancer
therapy.
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2. Exosomes and Cancer
2.1. Characterization of Tumor-Derived Exosomes. Exosome-
mediated intercellular communication requires fine regu-
lation that in cancer cells may be overcome; this allows
microenvironment alterations and the delivery of specific
tumor growth promoting signals.
Characterization studies highlighted that EVs composi-
tion profoundly differs between untransformed and tumor
cell lines [5–7]. RNA and protein contents, specific for
distinct exosome pools, may represent potential noninvasive
diagnostic markers: for instance, analysis of exosome RNA
cargoes in ovarian cancer and lung adenocarcinoma reveals
that microRNA profiling of circulating tumor exosomes is
different from the intracellular profiling [8, 9]. Furthermore,
specific exosomal microRNAs emerge as potential biomark-
ers of esophageal squamous cell cancer [10, 11]. In addition
potential markers have been identified among tumor-derived
exosome-enriched proteins: (i) the cell surface proteogly-
can Glypican-1 (GPC-1), expressed on serum exosomes,
discriminates patients with pancreatic cancer from those
with chronic pancreatitis [12]; (ii) exosomes isolated from
ovarian cancer patients’ plasma, but not from healthy con-
trols or patients with benign tumors, carry TGF-𝛽1 and
MAGE3/6 [13]; (iii) aggressive human glioma cells express
an epidermal growth factor receptor EGFRvIII variant that
may be transferred by tumor-derived exosomes to cells
lacking it, leading to the horizontal transfer of oncogenic
activity [14].
Themechanisms of selective loading of protein and RNAs
in EVs are still poorly understood, but there is evidence that
microenvironmental acidic pH [15] and hypoxia [16] might
affect both the quantity of released EVs and their content.
Indeed, the analysis of malignant effusions showed abundant
EVs release by tumor cells [9, 10].
2.2. Role of Tumor-Derived Exosomes in Metastasis. TDEs
may drive different oncogenic signals in autocrine, paracrine,
or endocrine manner [17, 18] and growing evidence points
to their role in different steps of metastasis. TDEs play a key
role in the initiation phase of the epithelial tumor metastasis,
carrying epithelial-mesenchymal transition (EMT) inducer
molecules, such as Notch-1 or hypoxia-inducible factor 1
(HIF1𝛼), and several metalloproteinases (MMPs) [19–23]. All
of these molecules are able to promote motility and inva-
siveness in recipient epithelial cells, conferring to them mes-
enchymal properties. In situ tumor cells can lose adhesion
and acquire the ability to migrate out of the primary tumor,
invading basement membrane and entering lymphatic and
hematic vasculature. After reaching potentially secondary
tumor sites, tumor cells can exit from circulation andmigrate
into the tissue parenchyma.These initial phases of the epithe-
lial tumor metastasis imply EMT transdifferentiation by
which differentiated cells lose their cell-cell contacts and the
epithelial phenotype, acquiring mesenchymal markers and
the ability to migrate. Conversely, a reverse mesenchymal-
epithelial transition (MET) supports the tumor cell growth
in secondary sites [24].
Recent observations also attribute to TDEs the ability
to promote the organotropism of metastatic tumors, con-
tributing to premetastatic niche formation: exosomes show
“avidity” for specific recipient cells that, in turn, are able to
internalize these vesicles [25–27]. In particular, Hoshino and
colleagues showed that the presence of exosomal integrins
𝛼6𝛽4 and 𝛼6𝛽1 is associated with lung metastasis, while
𝛼v𝛽5 is linked to liver metastasis. These surface proteins
are able to guide the exosomes to specific secondary sites,
where the fusion of the vesicles with resident cells prepares
the premetastatic niche: exosomes from lung-, liver-, and
brain-tropic tumor cells preferentially fuse with resident cells
at their selected destination, that is, lung fibroblasts and
epithelial cells, liver Kupffer cells, and brain endothelial cells
[27].
Furthermore, tumor exosomes may have immunomod-
ulatory properties, influencing T cell function and tumor
escape from immune surveillance [28, 29]. Immunosuppres-
sive TDEs can be found in neoplastic lesions and sera of
patients. One proposed mechanism for T cell suppression is
the extracellular adenosine production by exosomes exposing
CD39 and CD37 on their surface [29]. Moreover, Costa-Silva
and colleagues reported that, in the liver, the internalization
by Kupffer cells of TDEs produced by pancreatic duc-
tal adenocarcinomas induced fibronectin production that,
in turn, promoted the gathering of bone marrow-derived
macrophages and neutrophils, ultimately leading to liver
premetastatic niche formation [26].
3. The Role of Exosomes in HCC
3.1. Exosome-MediatedCellular Interplay inHCC. In the liver,
exosomes are secreted by hepatocytes, nonparenchymal liver
cells (i.e., stellate cells) and immune cells (i.e., T and B cells,
Kupffer cells, andnatural killer cells) and the cellular interplay
mediated by these vesicles holds important functions in
liver homeostasis. Exosome content, indeed, impacts on
proliferation of hepatocyte after injury [30], while exosomes
from bile control proliferation of cholangiocyte [31]. More-
over, exosomes secreted by primary hepatocytes promote
the activation of stellate cells by means of the specific RNA
cargoes [32]. Upon lipid-induced signaling, EVs released
from hepatocytes also cause a macrophages inflammatory
phenotype [33]. Another important functionmay be ascribed
to exosomes secreted by stellate cells and involved in fibrosis
[34]. Proteomic analysis of molecules sorted in hepatocyte
exosomes reveals the presence in these vesicles of several
enzymes that are involved in the metabolism of endogenous
and xenobiotic compounds, suggesting a role for exosomes in
spreading hepatic metabolizing functions in secondary sites
[35].
HCC is a prevalent worldwide liver cancer and the sixth
most lethal malignancy [36]. Appropriate markers for early
diagnosis of this tumor are still lacking and, currently, resec-
tion, liver transplant, interventional radiology treatment, and
chemoembolization for unresectable HCC remain the main
choices forHCC therapy, even if the survival benefit is limited
[37]. HCC shows a high risk of recurrence and its metastasis
is strongly influenced by microenvironment factors.
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Recent studies indicate that exchange of RNAs and
proteins via exosomes could not only have a key role in HCC
onset and progression butmay represent a source of potential
real-time, noninvasive biomarkers as well as therapeutic
targets.
In HCC, cells generally release high levels of exosomes
whose involvement in pathogenesis is currently under inves-
tigation. Although the identification in HCC of diagnostic
and prognostic exosome biomarkers is still at the initial
stage, there are encouraging observations that HCC cells
produce exosomes that are different from untransformed
cells in both RNA and protein content [38, 39]. Specifically,
He and colleagues characterized the exosome cargoes of three
metastatic HCC cell lines by proteomic analysis and RNA
deep sequencing. Among the identified molecules, several
oncogenic mRNAs and some proteins (i.e., the receptor tyro-
sine kinase MET, S100 family members, and Caveolin 1 and
2) were found highly enriched in exosomes. Moreover, the
same authors reported the horizontal transfer, via exosomes,
of molecules activating PI3K/AKT and MAPK signaling
pathways which conferred migratory capacity to noninvasive
hepatocytes [39]. Interestingly, Qu et al. demonstrated a
key role for HCC cell-derived exosomes in drug resistance
by activating the HGF/c-Met/Akt signaling pathway and
inhibiting apoptosis [40].
3.2. Exosome-Enriched Noncoding RNAs in HCC. After the
discovery of exosome-mediated transfer of mRNA and
microRNAs in 2007 [41], growing evidence has proven that
exosomes may carry different classes of functional RNAs that
may also represent useful diagnostic biomarkers. In HCC,
extensive research has been conducted on noncoding RNA
circulating molecules that can be isolated either from total
serum/plasma or from serum EVs and could be useful for
diagnostic applications [42].
SelectedmiRNAs are enriched in exosomes released from
HCC cells in vitro (e.g., miR-584, miR-517c, miR-378, miR-
520f, miR142-5p, miR-451, miR-518d, miR-215, miR-376a,
miR-133b, and miR-367 [38]) and in vivo (miR-10b and miR-
21 [43]). Exosomal miRNAs have been investigated as possi-
ble biomarkers to diagnose HCC in cirrhotic patients. Sohn
et al. isolated exosomes from the serum of chronic hepatitis B
(CHB) [44], cirrhosis, and HCC patients and found elevated
levels of miRNAs, such as miR-18a, miR-221, miR-222, and
miR-224, in HCC patients compared to those with CHB or
liver cirrhosis. Meanwhile, serum levels of miR-101, miR-
106b, miR-122, and miR-195 were lower in HCC patients
compared to CHB patients. Fornari and colleagues reported
the secretion of miR-519d, miR-21, miR-221a, and miR-1228
in exosomes from HCC patients and a correlation between
circulating and tissue levels formiR-519d, miR-494, andmiR-
21 [45]. Finally, Sugimachi et al. [46] explored biomarkers
in serum exosomes that may predict HCC recurrence after
surgery.
With regard to the functions and potential gene targets
of the candidate miRs, it was found that exosomal miR-
718 was negatively regulated in aggressive tumors, while
HOXB8 gene, potential miR target, was upregulated [46].
Furthermore, Liu et al. [47] investigated the diagnostic and
prognostic performance of the exosomal miR-21 in hepato-
blastoma (HB), a common liver primary malignant tumor of
the young children, highlighting increased levels of miR 21 in
exosomes comparedwith the exosome-depleted supernatants
and whole plasma.
Increasing evidence also pointed to a role for lncRNAs
as signaling molecules in HCC as well as the potential of
exosomes as vehicles to transfer them.
Mammalian genomes produce thousands of long non-
coding transcripts, heterogeneous class of molecules greater
than 200 nucleotides in length, thatmay form complexes with
other nucleic acids and proteins inside the cell and that are
involved in distinct biological functions [48].These lncRNAs
can act as promoters of HCC (e.g., the HOX Transcript
Antisense Intergenic RNA HOTAIR, MALAT1, and HULC)
[49–51] as well as tumor suppressors (e.g., p53 regulation-
associated lncRNA PRAL and CPS1-IT1) [52, 53] and several
of them are involved in epigenetic mechanisms of gene
expression regulation [54].
To date, few lncRNAs (i.e., VLDLR, ROR, and TUC339)
have been reported in circulating HCC EVs: (i) exposure
of HCC cells to diverse anticancer agents such as sorafenib,
camptothecin, and doxorubicin increased the expression of
lnc-VLDLR in transformed hepatocytes as well as its recruit-
ment inside EVs released from these cells.These data indicate
that this lncRNA could mediate the resistance to chemother-
apeutic stress inHCC cells [55]; (ii) another lncRNA involved
in HCC resistance against microenvironment conditions is
the regulator of reprogramming (ROR). Lnc-ROR has a role
in triggering epithelial-mesenchymal transition, cancer stem
cell maintenance, and tumorigenesis promotion. While the
expression of this lncRNA is low in normal hepatocytes, its
selective enrichment within EVs correlated with the TGF𝛽-
dependent HCC cells chemoresistance, whereas knockdown
of the same lncRNA enhanced the chemosensitivity [56]; (iii)
the lncRNA TUC339 was found significantly expressed in
EVs derived from HCC cells and was implicated in tumor
growth, cell adhesion, and cell cycle progression [57, 58].
Another lncRNA, the lncRNA H19, was specifically
enriched in exosomes secreted by CD90+ cells, having a
cancer stem cell- (CSC-) like aggressive phenotype; these
EVs modulate endothelial cells adhesion and angiogenic
phenotype [59].
Several lncRNAs have been recently detected in whole
plasma of HCC patients [52] but further studies are required
to clarify if they are also enriched in the correspondent
exosomal fraction. This analysis could also require better
standardization of preanalytical steps (sample collection and
storage), sample processing, and normalization, taking into
account the fact that lncRNAs are often low-copy molecules.
The lncRNAs urothelial carcinoma associated-1 (lncRNA-
UCA1) and WD repeat containing antisense to TP53 (lnc-
WRAP53) were found significantly higher in sera of HCC
patients with respect to chronic HCV infected patients or
healthy volunteers [60]. Notably, UCA1 may act as a sponge
for the miR-126b, targeting FGFR1. Indeed, UCA1 depletion
regulates growth andmetastasis of HCC cell lines in vitro and
in vivo [61].
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Li et al. [62] found the lncRNA HULC (Highly Upreg-
ulated in Liver Cancer) significantly upregulated in HCC
patients’ plasma. Interestingly, this lncRNA, which is highly
expressed in HCC [63], serves as a competing endogenous
RNA (ceRNA), by sequestering miR-200a-3p, during EMT
progression, leading to upregulation of the EMT-master
regulator ZEB1 and promoting metastasis [64]. HULC was
also found to contain miR-372 binding sites: its overexpres-
sion, indeed, reduces miR-372 levels leading to a regulatory
circuitry which involves CREB and plays a role in cell repro-
gramming [50].Moreover, Yu andColleagues, by comparison
between the expression levels of 31 cancer-related lncRNAs
in HCC patients and healthy individuals’ sera, identified the
lnCRNA PVT1 and uc002mbe.2 as possible biomarkers [65].
Other lncRNAs (i.e., HOTAIR, MALAT1, and MEG3)
have been demonstrated to be sorted in TDEs [66]; how-
ever, to our knowledge no data about their presence in
HCC exosomes are available. HOTAIR (for HOX Transcript
Antisense Intergenic RNA) is a cellular low-copy lncRNA
enriched in exosomes of HeLa and MCF-7 cells [67]. It is
overexpressed in HCC tissues and liver cancer cell lines
[68, 69] and high HOTAIR levels positively correlate to
poorer prognosis and larger tumor size [70]. This lncRNA is
involved in the targeting of Polycomb Repressive Complex
2 (PRC2) to specific genomic sites [71] and, notably, its key
role in epithelial-to-mesenchymal transition of hepatocytes
was recently described [72]. In the light of the informational
content of HOTAIR, it is conceivable that it could represent
a cargo molecule of HCC TDEs as well as the lncRNAs
MALAT1 and MEG3, sorted in exosomes from HeLa and
MCF-7 cells [66]. These lncRNAs are deregulated in HCC
tumoral tissuewith respect to normal liver [49, 73]. Also these
lncRNAs are able to bind and recruit epigenetic modifiers on
specific genomic loci, ultimately resulting in deregulation of
the gene expression relevant to HCC development [54].
4. Exosome-Mediated Therapeutic Approaches
Exosome cargo is represented by easily identifiable molecules
that reflect the cell of origin as well as the contribution of
the immune context and tumormicroenvironment.Thus, the
characterization of EVs, as a source of biomarkers through
bio fluids, can provide an appealing real-time, noninvasive
means of monitoring the course of tumor progression, with
promising applications ranging from diagnosis to treatment
[74–76].
Moreover, exosomes may be efficiently used in antitu-
mor therapies, stimulating the immune response: Zitvogel
and colleagues, in a pioneering work, demonstrated that
exosome-based cell-free vaccines can represent a valid anti-
tumor approach alternative to dendritic cells (DCs) adoptive
therapy. Exosomes, indeed, can prime specific cytotoxic T
lymphocytes in vivo and suppress the growth of established
murine tumors in a T cell-dependent manner [77]. Recently,
Morishita et al. [78] obtained an exosome-based tumor
antigen-adjuvant codelivery system for cancer immunother-
apy by engineering tumor exosomes and expressing on their
surface a fusion protein able to bind biotinylated CpG DNA.
Rao et al. [79] recently demonstrated that TDEs determine
tumor suppression in HCC models: these authors used exo-
somes derived from HCC cells, which display HCC antigens,
to activate dendritic cells. These cells showed a stronger
immune response with respect to their counterpart being
activated by cancer cell lysates. Tumor growth inhibition
was found in ectopic and orthotropic HCC mice treated
by dendritic cells pulsed with tumor exosomes. In addition,
this approach allowed an efficient HCC-specific cytolysis
in human HCC cells, independently of human leukocyte
antigens (HLA).
Other strategies aim to promote antitumor response by
using combination of exosomes and appropriate immune-
stimulatory adjuvants, to suppress immune-inhibitory effects
[80]. For example, a chemo/immunotherapy was established
in advanced ovarian cancer by using TDEs and a Toll-like
receptor 3 (TLR3) agonist [81].
Exosomes show low immunogenicity and toxicity and are
quite stable, in tissues as well as in circulation; thus they
appear as better vehicles for delivery of chemotherapeutics
in tumor therapeutic approaches with respect to previously
used synthetic ones (such as liposomes) (for review [80]).
In an example of chemotherapeutic delivery, doxorubicin
(DOX) was loaded via electroporation into exosomes of
immature dendritic cells (imDCs), engineered to express a
known exosomal protein (Lamp2b), and fused to 𝛼v integrin-
specific iRGDpeptide. Intravenous injection of these targeted
exosomes delivered DOX specifically to tumor tissues [82].
To achieve targeted delivery to tumor cells and improve
therapeutic applicability, the EVs tropism can be modified by
means of the genetic engineering of cells of origin or bymod-
ification of EV membrane proteins. Kooijmans et al. recently
described the transfection of cells with vectors encoding for
anti-epidermal growth factor receptor (EGFR) nanobodies,
fused to glycosylphosphatidylinositol (GPI) anchor signal
peptides. GPI-linked nanobodies were successfully displayed
on the surface of the secreted EVs, altering their targeting
[83].
Moreover, with respect to the possible EVs clearance by
the monocyte/macrophage and reticuloendothelial system,
Watson et al. [84] recently identified the Scavenger Receptor
Class A (SR-A) as a major uptake receptor for EVs on mono-
cyte/macrophages. They showed the successful prevention of
the massive EVs liver clearance through in vivo blockade of
SR-A with dextran sulfate.
EVs are also attractive candidate for the delivery of
different drug types. In particular, small RNAs, such as miR-
NAs, naturally shuttled by exosomes [41], may be efficiently
loaded in exosomes for gene therapy approaches; analogously,
exosome loaded with synthetic siRNAs can mediate specific
RNA interference silencing after fusion with target cells (for
review [44]). The proposed approaches imply the loading
of the RNA molecules in isolated exosomes. Electroporation
was used to introduce siRNAs in human peripheral blood
exosomes to cause gene silencing of mitogen-activated pro-
tein kinase 1 [85] as well as siRNAs against Alpha-synuclein
(𝛼-Syn, which aggregates are characteristic pathological fea-
ture of the Parkinson’s disease (PD) brain) [86]. These
exosomes were successfully tested in experimental disease
models.
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Figure 1: Summary of the specific composition of HCC exosome. Known exosomal markers (such as tetraspanins and TSG101), as well as
HCC exosome-enriched proteins and RNAs, are represented in the scheme.
Alternatively, specific stimuli can be used to enhance
sorting of specific classes of miRNAs by the cell exploiting,
in this case, the preexisting cellular machinery: for instance,
blood cells and cultured THP-1 cells actively and selectively
package miRNAs into EVs and secrete them in different cell
conditions [87]. For instance, Xiao et al. reported the increase
in exosome secretion of MICB and HSP70 from HepG2
cells upon treatment with the histone deacetylase inhibitor
(HDACi) drug MS-275, demonstrating an enhancement of
the immunomodulatory function of HCC exosome cargoes
after chemotherapy [88].While it appears evident that exoso-
mal miRNAs play a functional role in the modulation of the
cellularmicroenvironment and that exosomal sorting of these
RNAs is deregulated in cancer, current knowledge on the
regulation of specific RNAs sorting is still poor. Significantly,
recent reports identified new players of sequence-specific
miRNA exosomal loading process: Villaroya-Beltri and col-
leagues [89], in lymphocytes, and Santangelo et al. [90], in
hepatocytes, identified two short sequences, respectively, the
so-called EXO- [89] and hEXO-motifs [90], able to guide
miRNA loading. Both of these motifs have a functional
role in the sorting process; indeed the insertion of EXO-
or hEXO-sequence in a cell-retained miRNA induced its
exosomal export. Moreover, these sequence determinants are
specifically bound by specific RNA-binding proteins: in par-
ticular, the Heterogeneous Nuclear Ribonucleoprotein A2B1
(hnRNPA2B1) binds the EXO-motif and the Synaptotagmin-
binding Cytoplasmic RNA-Interacting Protein (SYNCRIP,
also known as hnRNP-Q or NSAP1) binds to the hEXO-
motif. Furthermore, the functional role of these proteins in
the process of exosomal miRNA sorting was demonstrated
by silencing approaches.
5. Conclusions and Perspectives
Early diagnosis of HCC is still very difficult and the devel-
opment of noninvasive diagnostic tools represents a major
challenge. The recent identification of distinct noncoding
RNAs (i.e., miRNAs and lncRNAs) enriched in HCC exo-
somes strongly encourages the use of thesemolecules as novel
HCC biomarkers (Figure 1). Exosome-enriched ncRNAs are
actively sorted and can be used for noninvasive real-time
staging of tumor evolution and response to therapy. Notably,
while more efforts are needed to clarify the involvement of
specific exosome cargo molecules in regulating HCC onset
and progression, recent findings already suggest a key role for
miRNAs and lncRNAs.
Exosomes have recently gathered research interest for
antitumor therapeutic approaches, representing active drug
components (modulating the immune responses and induc-
ing antitumor responses) as well as drug delivery systems.
Further efforts are needed in the engineering of exosomes
allowing them to convey molecules of interest (e.g., miRNAs
and/or siRNAs). These specific signals could be conceivably
addressed to achieve targeted therapeutic intervention. The
recent discovery of the mechanism of sequence-specific
miRNA exosomal loading process opens the way for possible
selective modification of the miRNAs exosomal cargo by
engineering of the EXO- and hEXO-motifs [89, 90].
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